Login to Your Account



Clinic Roundup


Monday, November 4, 2013
• Cevec Pharmaceuticals GmbH, of Cologne, Germany, said a Dutch consortium led by TNO and including biopharma firm Alloksys Life Sciences BV, of Utrecht, the Netherlands, reported the safe completion of a Phase I study of recombinant human alkaline phosphatase (hRESCAP) derived from Cevec’s CAP cells, immortalized suspension cells for stable protein production.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription